Compare OFS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFS | ACET |
|---|---|---|
| Founded | 2001 | 1947 |
| Country | United States | United States |
| Employees | N/A | 102 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.3M | 33.5M |
| IPO Year | 2010 | 2017 |
| Metric | OFS | ACET |
|---|---|---|
| Price | $3.67 | $3.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $34.83 |
| AVG Volume (30 Days) | 76.1K | ★ 187.5K |
| Earning Date | 10-29-2026 | 11-13-2026 |
| Dividend Yield | ★ 16.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $0.46 |
| 52 Week High | $5.81 | $9.97 |
| Indicator | OFS | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 38.98 | 18.83 |
| Support Level | $3.51 | N/A |
| Resistance Level | $4.07 | $9.59 |
| Average True Range (ATR) | 0.14 | 0.34 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 29.39 | 3.39 |
OFS Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objective is to provide its stockholders with both current income and capital appreciation through debt investments and, to a lesser extent, equity investments.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).